Ceruloplasmin Expression in Rat Liver Cells is Attenuated by Insulin: Role of FoxO Transcription Factors

Abstract

The phosphoinositide 3′-kinase (PI3 K)/Akt pathway controls the activity of a number of proteins important in the regulation of apoptosis and cell proliferation. FoxO (forkhead box, class O) transcription factors, substrates of the Ser/Thr kinase Akt, control the expression of several target genes that are crucial to the defense against oxidative stress, the regulation of cell cycle, and apoptosis in mammalian cells. Here, expression of ceruloplasmin (CP), the major copper-containing protein in blood released by the liver, was investigated. We observed a significant downregulation of CP mRNA levels after insulin treatment in H4IIE rat hepatoma cells. The PI3K inhibitor wortmannin counteracted this insulin effect on CP mRNA levels, indicating that the PI3K/Akt cascade is involved in the regulation of CP expression. Stimulation of FoxO1 was induced in H4IIE rat hepatoma cells expressing a conditionally active FoxO1 construct, resulting in significant upregulation of CP mRNA levels. This upregulation was prevented in the presence of insulin. In parallel, mRNAs of established FoxO target genes were analyzed: like CP mRNA, selenoprotein P and glucose 6-phosphatase mRNAs were upregulated by FoxO1, which was prevented by insulin. The same effects of insulin on CP mRNA levels were detected in primary rat hepatocytes. Furthermore, CP release into cell culture media was analyzed with primary hepatocytes and found to be attenuated by insulin. In line with its insulin-mimetic effects on cultured cells, Cu²⁺ imitated the effect of insulin on CP expression and caused a downregulation of CP mRNA levels in rat hepatoma cells.

ceruloplasmin - liver - insulin - FoxO - oxidative stress - copper - diabetes mellitus

References

• 1 Nittis T, Gitlin JD. The copper-iron connection: hereditary aceruloplasminemia.  Semin Hematol. 2002;  39 282-289
• 2 Shukla N, Maher J, Masters J, Angelini GD, Jeremy JY. Does oxidative stress change ceruloplasmin from a protective to a vasculopathic factor?.  Atherosclerosis. 2006;  187 238-250
• 3 Atanasiu RL, Stea D, Mateescu MA, Vergely C, Dalloz F, Briot F, Maupoil V, Nadeau R, Rochette L. Direct evidence of caeruloplasmin antioxidant properties.  Mol Cell Biochem. 1998;  189 127-135
• 4 Hellman NE, Gitlin JD. Ceruloplasmin metabolism and function.  Annu Rev Nutr. 2002;  22 439-458
• 5 Harris ZL, Takahashi Y, Miyajima H, Serizawa M, MacGillivray RT, Gitlin JD. Aceruloplasminemia: molecular characterization of this disorder of iron metabolism.  Proc Natl Acad Sci USA. 1995;  92 2539-2543
• 6 Ehrenwald E, Chisolm GM, Fox PL. Intact human ceruloplasmin oxidatively modifies low density lipoprotein.  J Clin Invest. 1994;  93 1493-1501
• 7 Mukhopadhyay CK, Mazumder B, Lindley PF, Fox PL. Identification of the prooxidant site of human ceruloplasmin: a model for oxidative damage by copper bound to protein surfaces.  Proc Natl Acad Sci USA. 1997;  94 11546-11551
• 8 Leoni V, Albertini R, Passi A, Abuja PM, Borroni P, D’Eril GM, De LG. Glucose accelerates copper- and ceruloplasmin-induced oxidation of low-density lipoprotein and whole serum.  Free Radic Res. 2002;  36 521-529
• 9 Choi SY, Kwon HY, Kwon OB, Eum WS, Kang JH. Fragmentation of human ceruloplasmin induced by hydrogen peroxide.  Biochimie. 2000;  82 175-180
• 10 Kim RH, Park JE, Park JW. Ceruloplasmin enhances DNA damage induced by hydrogen peroxide in vitro.  Free Radic Res. 2000;  33 81-89
• 11 Cunningham J, Leffell M, Mearkle P, Harmatz P. Elevated plasma ceruloplasmin in insulin-dependent diabetes mellitus: evidence for increased oxidative stress as a variable complication.  Metabolism. 1995;  44 996-999
• 12 Daimon M, Sugiyama K, Saitoh T, Yamaguchi H, Hirata A, Ohnuma H, Igarashi M, Eguchi H, Manaka H, Kato T. Increase in serum ceruloplasmin levels is correlated with a decrease of serum nitric oxide levels in type 2 diabetes.  Diabetes Care. 2000;  23 559-560
• 13 Mabayoje VO, Akanni EO, Arinola GO, Hassan RO. Plasma transferrin and caeruloplasmin levels in Nigerians with diabetes mellitus.  Int J Trop Med. 2010;  5 69
• 14 Liu Z, Barrett EJ, Dalkin AC, Zwart AD, Chou JY. Effect of acute diabetes on rat hepatic glucose-6-phosphatase activity and its messenger RNA level.  Biochem Biophys Res Commun. 1994;  205 680-686
• 15 Schmoll D, Walker KS, Alessi DR, Grempler R, Burchell A, Guo S, Walther R, Unterman TG. Regulation of glucose-6-phosphatase gene expression by protein kinase Balpha and the forkhead transcription factor FKHR. Evidence for insulin response unit-dependent and -independent effects of insulin on promoter activity.  J Biol Chem. 2000;  275 36324-36333
• 16 Barthel A, Schmoll D, Krüger KD, Bahrenberg G, Walther R, Roth RA, Joost HG. Differential regulation of endogenous glucose-6-phosphatase and phosphoenolpyruvate carboxykinase gene expression by the forkhead transcription factor FKHR in H4IIE-hepatoma cells.  Biochem Biophys Res Commun. 2001;  285 897-902
• 17 Barthel A, Orth HM, Krüger KD, Schmoll D, Joost HG. Construction and characterization of a conditionally active construct of the insulin-regulated forkhead transcription factor FKHR.  Exp Clin Endocrinol Diabetes. 2002;  110 304-309
• 18 Reinehr R, Graf D, Fischer R, Schliess F, Haussinger D. Hyperosmolarity triggers CD95 membrane trafficking and sensitizes rat hepatocytes toward CD95L-induced apoptosis.  Hepatology. 2002;  36 602-614
• 19 Schmoll D, Allan BB, Burchell A. Cloning and sequencing of the 5′ region of the human glucose-6-phosphatase gene: transcriptional regulation by cAMP, insulin and glucocorticoids in H4IIE hepatoma cells.  FEBS Lett. 1996;  383 63-66
• 20 Furuyama T, Nakazawa T, Nakano I, Mori N. Identification of the differential distribution patterns of mRNAs and consensus binding sequences for mouse DAF-16 homologues.  Biochem J. 2000;  349 629-634
• 21 Barthel A, Schmoll D, Unterman TG. FoxO proteins in insulin action and metabolism.  Trends Endocrinol Metab. 2005;  16 183-189
• 22 Speckmann B, Walter PL, Alili L, Reinehr R, Sies H, Klotz LO, Steinbrenner H. Selenoprotein P expression is controlled through interaction of the coactivator PGC-1alpha with FoxO1a and hepatocyte nuclear factor 4alpha transcription factors.  Hepatology. 2008;  48 1998-2006
• 23 Walter PL, Steinbrenner H, Barthel A, Klotz LO. Stimulation of selenoprotein P promoter activity in hepatoma cells by FoxO1a transcription factor.  Biochem Biophys Res Commun. 2008;  365 316-321
• 24 Walter PL, Kampkötter A, Eckers A, Barthel A, Schmoll D, Sies H, Klotz LO. Modulation of FoxO signaling in human hepatoma cells by exposure to copper or zinc ions.  Arch Biochem Biophys. 2006;  454 107-113
• 25 Barthel A, Klotz LO. Phosphoinositide 3-kinase signaling in the cellular response to oxidative stress.  Biol Chem. 2005;  386 207-216
• 26 Schinner S, Scherbaum WA, Bornstein SR, Barthel A. Molecular mechanisms of insulin resistance.  Diabet Med. 2005;  22 674-682
• 27 Gutteridge JM, Stocks J. Caeruloplasmin: physiological and pathological perspectives.  Crit Rev Clin Lab Sci. 1981;  14 257-329
• 28 Memisogullari R, Bakan E. Levels of ceruloplasmin, transferrin, and lipid peroxidation in the serum of patients with Type 2 diabetes mellitus.  J Diabetes Complications. 2004;  18 193-197
• 29 Misu H, Takamura T, Takayama H, Hayashi H, Matsuzawa-Nagata N, Kurita S, Ishikura K, Ando H, Takeshita Y, Ota T, Sakurai M, Yamashita T, Mizukoshi E, Yamashita T, Honda M, Miyamoto K, Kubota T, Kubota N, Kadowaki T, Kim HJ, Lee IK, Minokoshi Y, Saito Y, Takahashi K, Yamada Y, Takakura N, Kaneko S. A liver-derived secretory protein, selenoprotein P, causes insulin resistance.  Cell Metab. 2010;  12 483-495
• 30 Ishigaki Y, Oka Y, Katagiri H. Circulating oxidized LDL: a biomarker and a pathogenic factor.  Curr Opin Lipidol. 2009;  20 363-369
• 31 Liao JK, Shin WS, Lee WY, Clark SL. Oxidized low-density lipoprotein decreases the expression of endothelial nitric oxide synthase.  J Biol Chem. 1995;  270 319-324
• 32 Hein TW, Liao JC, Kuo L. oxLDL specifically impairs endothelium-dependent, NO-mediated dilation of coronary arterioles.  Am J Physiol Heart Circ Physiol. 2000;  278 H175-H183
• 33 Djaberi R, Beishuizen ED, Pereira AM, Rabelink TJ, Smit JW, Tamsma JT, Huisman MV, Jukema JW. Non-invasive cardiac imaging techniques and vascular tools for the assessment of cardiovascular disease in type 2 diabetes mellitus.  Diabetologia. 2008;  51 1581-1593
• 34 Olivares M, Mendez MA, Astudillo PA, Pizarro F. Present situation of biomarkers for copper status.  Am J Clin Nutr. 2008;  88 859S-862S
• 35 Harvey LJ, Ashton K, Hooper L, Casgrain A, Fairweather-Tait SJ. Methods of assessment of copper status in humans: a systematic review.  Am J Clin Nutr. 2009;  89 2009S-2024S

Correspondence